AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca has paused global trials of its experimental coronavirus vaccine after an unexplained illness in a participant, denting the British drugmaker's shares as the move was seen as dimming prospects for an early rollout.

Factbox: Scientists, drugmakers and traders react to AstraZeneca's COVID-19 vaccine trial pause

U.S. infectious disease expert Anthony Fauci said on Wednesday that AstraZeneca's decision to pause global trials of its experimental coronavirus vaccine was unfortunate but not an uncommon safety precaution in a vaccine development process.

Fauci says Astrazeneca vaccine pause unfortunate, not uncommon

Tests have been paused after a UK volunteer became ill. How will it affect the search for a cure?

Oxford Covid vaccine trial suspension: what happens next?

GlaxoSmithKline

Johnson & Johnson

Moderna

Novavax

Sanofi

These healthcare companies have had plenty of help in building the manufacturing capacity needed to produce billions of vaccine doses.

6 Companies Racing to Mass-Produce a Coronavirus Vaccine in 2021

AstraZeneca has paused global trials of its experimental coronavirus vaccine after an unexplained illness in a participant, denting the British drugmaker's shares on Wednesday as the move was seen as dimming prospects for an early rollout.

AstraZeneca pauses coronavirus vaccine trial, rollout doubts dent shares

The U.K.'s health minister on Wednesday rushed to defend AstraZeneca's decision to pause a closely-watched coronavirus vaccine trial due to safety concerns.

AstraZeneca trial pause is ‘not necessarily’ a setback, British health minister says

WASHINGTON--(BUSINESS WIRE)--Halt of AstraZeneca’s COVID Vax Trial Exposes the Downside Risk of Rushing

Halt of AstraZeneca’s COVID Vax Trial Exposes the Downside Risk of Rushing

AstraZeneca Plc (NYSE: AZN) shares tanked in the after-hours session Tuesday, as the British drugmaker said it has temporarily halted the advanced trials of its COVID-19 vaccine to allow for a review of safety data by an independent committee.

AstraZeneca Shares Drop 8% As Advanced COVID-19 Vaccine Trials Are Halted

The trial was put on hold after a participant was suspected of developing a serious adverse reaction.

AstraZeneca Puts Phase 3 Vaccine Trial On Hold, Shares Drop 6%

The phase 3 clinical trial has been paused while researchers investigate what caused the reaction.

Oxford coronavirus vaccine trial on hold after adverse reaction in participant

One participant fell ill, but the connection to treatment with AZD122 is unclear.

AstraZeneca Coronavirus Vaccine Clinical Trial Paused

U.S.-traded shares of AstraZeneca PLC AZN, +2.10% fell in the extended session Tuesday following a report that the drug maker halted a COVID-19 vaccine study following an adverse reaction from a participant.

AstraZeneca’s U.S. stock falls on report of coronavirus study halt

AstraZeneca shares fell more than 6% in after-hours trading Tuesday after the company said its late-stage trial for a potential coronavirus vaccine had been put on hold due to safety concerns.

AstraZeneca shares drop 6% after company announces 'routine' safety pause in vaccine trial

BioNTech SE

The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others.

What Does a Perfect COVID-19 Vaccine Actually Mean?

Horizon Pharma

Eli Lilly

Dr. Reddy's Labs

Repligen

Zoetis

The pandemic isn't the only reason you should be looking a pharmaceutical stocks. Here are six pharma companies that stand out with or without Covid-19.

6 of the Best Pharmaceutical Stocks to Buy Today

AstraZeneca's (AZN) shares are up this year mainly due to rapid progress in its efforts to make a vaccine to treat COVID-19 as well as other positive pipeline and regulatory updates.

Here's Why AstraZeneca (AZN) Stock is Up This Year So Far

Merck

Pfizer

Nine leading U.S. and European vaccine developers pledged to uphold the scientific standards that their experimental immunizations will be held against, amid a hurried global race to contain the pandemic.

Nine biopharma CEOs pledge to make safety the main focus in coronavirus vaccine development

NEW YORK, Sept.  08, 2020  (GLOBE NEWSWIRE) -- The CEOs of  AstraZeneca  (LSE/STO/NYSE: AZN),  BioNTech SE  (NASDAQ: BNTX),  GlaxoSmithKline plc  (LSE/NYSE: GSK),  Johnson & Johnson  (NYSE: JNJ),  Merck  (NYSE: MRK), known as MSD outside the United States and Canada,  Moderna, Inc.  (Nasdaq: MRNA),  Novavax, Inc.  (Nasdaq: NVAX),  Pfizer Inc.  (NYSE: PFE), and  Sanofi  (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.

Biopharma Leaders Unite to Stand with Science

The vaccine developers are likely to pledge to observe high ethical standards in conducting clinical studies and manufacturing of the vaccines, the Wall Street report said.

Coronavirus Vaccine Makers May Make Joint Safety Pledge

Abbott Labs

Want to get in on a coronavirus healthcare investment? It's not too late.

3 Top Coronavirus Stocks to Buy in September

Altimmune

Inovio Pharmaceuticals

Vaxart

How to Invest in Coronavirus Vaccine Stocks

A quick approval would be nice, but the drugmakers are sticking to their scientific principals.

Moderna, Pfizer, Johnson & Johnson, And Others To Make Pledge in Response to Coronavirus Vaccine Political Pressure

These businesses are backed by science, and they've already got orders lined up for their experimental vaccines.

Got $5,000? Invest It in Any of These 6 Coronavirus Vaccine Stocks

It's time to prep your portfolio for the next market downturn.

2 Top Coronavirus Vaccine Stocks to Buy When the Next Market Crash Comes

Yes, one or more COVID-19 vaccines could realistically be available before the end of the year.

3 Drugmakers Most Likely to Launch Coronavirus Vaccines in the U.S. by the End of 2020

News for AstraZeneca Stock (AZN)